Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,047 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Screening Only Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 16, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

LY3214996 +/- HCQ in Pancreatic Cancer

NCT04386057
View directory record Official record
Conditions
Pancreatic Cancer, Advanced Cancer
Interventions
Hydroxychloroquine Sulfate, LY3214996
Drug
Lead sponsor
Kimberly Perez, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 16, 2026, 10:48 PM EDT
Recruiting No phase listed Observational

Genetic and Metabolic Disease in Children

NCT02650622
View directory record Official record
Conditions
Genetic Diseases, Metabolic Diseases
Interventions
Skin Biopsy
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
1 Day and older
Enrollment
1,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 16, 2026, 10:48 PM EDT
Completed Not applicable Interventional Results available

Low-Level Laser Therapy for Plantar Fasciitis

NCT05763381
View directory record Official record
Conditions
Plantar Fascitis
Interventions
Photobiomodulation Therapy (PBMT), Sham-Photobiomodualtion Therapy (Sham-PBMT)
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 16, 2026, 10:48 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Techniques to Enhance Patient Comfort in Sedation-risk Free Colonoscopy

NCT01076907
View directory record Official record
Conditions
Screening of Colonic Polyps
Interventions
Warm water, Control
Other
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 95 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 16, 2026, 10:48 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Bundled Cancer Screening and Genetic Services Navigation

NCT07228000
View directory record Official record
Conditions
Breast Cancer Screening, Colon Cancer Screening, Genetics Predisposition
Interventions
Breast cancer screening navigation, Multicancer screening navigation, Usual care genetics referral, Pretest education + usual care genetics referral
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
45 Years to 74 Years · Female only
Enrollment
820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Newark, Delaware • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 16, 2026, 10:48 PM EDT
Withdrawn Not applicable Interventional

Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease

NCT00459225
View directory record Official record
Conditions
Anemia
Interventions
Iron (ferrous sulfate)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 2 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 16, 2026, 10:48 PM EDT
Not listed Not applicable Interventional

Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs

NCT06600724
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic, Foot Ulcer
Interventions
Standard of Care, EPIEFFECT, EPIXPRESS
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 16, 2026, 10:48 PM EDT
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 16, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Bioequivalence of a Combined Formulated Tablet

NCT01622790
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 16, 2026, 10:48 PM EDT
Completed No phase listed Observational Results available

Evaluating Cancer Survivorship Care Models

NCT02362750
View directory record Official record
Conditions
Quality of Life, Cancer
Interventions
Consultative Specialized Survivorship Clinic (CSSC), Longitudinal Specialized Survivorship Clinic (LSSC), Oncology Embedded Survivorship Clinic (OESC)
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 16, 2026, 10:48 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Galleri® in the Medicare Population.

NCT05673018
View directory record Official record
Conditions
Cancer
Interventions
Multi-Cancer Early Detection Test (Galleri®)
Device
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
61
States / cities
Fort Smith, Arkansas • Auburn, California • Davis, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 16, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Hearing Health Care Service Access and Use

NCT02037139
View directory record Official record
Conditions
Hearing Loss
Interventions
Screening, Brochure, Education
Other · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 16, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Choice Architecture and Mailed Colorectal Cancer Screening Outreach in a Community Health Setting

NCT04711473
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colonoscopy Only, Choice, FIT Only
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
50 Years to 74 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pottstown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 16, 2026, 10:48 PM EDT
Recruiting Phase 2 Interventional

Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer

NCT07718854
View directory record Official record
Conditions
Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer, Recurrent Ovarian Clear Cell Adenocarcinoma
Interventions
Sacituzumab tirumotecan, Pembrolizumab
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 16, 2026, 10:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Interactive Preventive Health Record to Increase Colorectal Cancer Screening

NCT01885351
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
MyCRCS+Prefs, MyCRCS+Prefs+Barriers
Behavioral
Lead sponsor
Temple University
Other
Eligibility
50 Years to 75 Years
Enrollment
683 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 16, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Registry and Screening Tool to Identify Children With Asthma Likely to Benefit From Home Assessment and Remediation

NCT03916237
View directory record Official record
Conditions
Asthma, Pediatric ALL, School Health Services, Registries, Medical Informatics, Home Visits, Housing Problems, Social Determinants of Health, Healthcare Disparity, Health Status Disparity
Interventions
Home assessment, Home remediation, Referral to Medical Legal Partnership, Regular School Based Health Asthma Care
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
5 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 16, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

NCT01698905
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 16, 2026, 10:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brief Alcohol Screening for Community College Students (BASICCS)

NCT04052386
View directory record Official record
Conditions
Alcohol; Use, Problem
Interventions
BASICCS
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 29 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 9, 2019 · Synced Oct 16, 2026, 10:48 PM EDT
Recruiting Not applicable Interventional

Preimplantation Genetic Testing in Women of Advanced Maternal Age

NCT04167748
View directory record Official record
Conditions
Infertility, Female
Interventions
Preimplantation genetic testing for aneuploidy (PGT-A)
Procedure
Lead sponsor
Genomic Prediction Inc.
Industry
Eligibility
35 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Margate, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 16, 2026, 10:48 PM EDT
Completed Phase 4 Interventional Results available

Myositis Interstitial Lung Disease Nintedanib Trial

NCT05799755
View directory record Official record
Conditions
Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions
Nintedanib, Placebo, Standard of Care
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 10:48 PM EDT
Completed Not applicable Interventional

The Effect of Time-Slot Scheduling and Active Choice on Biometric Screening Participation

NCT01305798
View directory record Official record
Conditions
Preventative Health
Interventions
Scheduling and Active Choice for Biometric Participation
Other
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 16, 2026, 10:48 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

NCT02275533
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Clinical Observation, Echocardiography Test, Nivolumab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 16, 2026, 10:48 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

NCT05583149
View directory record Official record
Conditions
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Interventions
ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
Drug
Lead sponsor
Patrick C. Johnson, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 16, 2026, 10:48 PM EDT